Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Filings indexed 1,392 across all filing types
Latest filing 2018-09-24 Transaction in Own Shar…
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
8-K
Transaction in Own Shares Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated September 20, 2018, by Ligand Pharmaceuticals Incorporated. The content describes the approval of a new share repurchase program authorizing up to $200 million in stock buybacks. It is not a full financial report but an announcement of a specific corporate action related to capital structure. The document length is 4408 characters, which is relatively short and consistent with a typical 8-K filing announcing a share repurchase program. This fits the category of Transaction in Own Shares (POS), which covers announcements of share repurchase programs or buybacks. There is no indication that this is a full annual or quarterly report, audit report, or other categories. Therefore, the correct classification is POS with high confidence.
2018-09-24 English
PRIMARY DOCUMENT
Director's Dealing
2018-09-19 English
4
Director's Dealing
2018-09-06 English
PRIMARY DOCUMENT
Director's Dealing
2018-09-06 English
PRIMARY DOCUMENT
Director's Dealing
2018-09-06 English
PRIMARY DOCUMENT
Director's Dealing
2018-09-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.